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ABTRACT
OBJECTIVE: The objective of this systematic review is to determine the safety and efficacy of
conjugated linoleic acid for weight loss in obese individuals.
STUDY DESIGN: Review of three English language primary studies published in 2004 and
2006.
DATA SOURCES: Randomized, double-blind, placebo-controlled trials comparing conjugated
linoleic acid to placebo were found using OVID MEDLINE and Cochrane Databases.
OUTCOMES MEASURED: Conjugated linoleic acid efficiency and adverse effects. In each
study, change in body weight, BMI, vital signs, and complete blood work was conducted at the
beginning, during set intervals, and at the end of the study. Adverse effects were measured by a
questionnaire used in each study at different intervals and at the end of the study. Blood work
was also examined for any adverse change in glucose, insulin, AST, and ALT levels.
RESULTS: Two studies found that conjugated linoleic acid is effective for weight loss. All three
trials found that there were no significant adverse effects or change in glucose, insulin, AST, and
ALT with long-term conjugated linoleic acid usage.
CONCLUSIONS: Conjugated linoleic acid has the potential to be an effective weight loss
supplement in obese individuals, but further studies are needed to determine its true efficiency.
Studies are needed that contain specific age ranges, equal gender distribution, and a variety in the
amount of conjugated linoleic acid studied. The results demonstrate that conjugated linoleic acid
is a safe drug to use, with minimal adverse effects.
KEY WORDS: conjugated linoleic acid, CLA, efficiency, safety, adverse effects, and obesity
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INTRODUCTION
Obesity is the leading cause of preventable death worldwide. Obesity affects over 75.2
million people, or about 65% of the population, in the United States. Obesity can lead to a
variety of diseases, including cardiovascular disease, diabetes mellitus type 2, obstructive sleep
apnea, certain cancers, and osteoarthritis. This condition has also been shown to reduce life
expectancy on average of up to 8 to 10 years. From 1987 to 2001, medical costs associated with
obesity accounted for 27% of the increases in medical costs in the U.S. In 2006, it was found that
medical costs for obesity were estimated to be $147 billion dollars. Obese persons have
estimated medical costs that are $1,429 higher than non-obese persons. In 2009, it was found that
at least 30% of adults were obese in nine states, compared to zero states in 2000. In 2009, over
65 million healthcare visits were obesity related1.
Obesity is characterized by excess body fat that accumulates and leads to adverse health
conditions. On the BMI scale, obesity is classified as over 30 kg/m2. Obesity has been considered
a direct result of a sedentary lifestyle with ingestion of excess calories. However, several studies
have shown a genetic link with the development of obesity, with as much as 40-70% of obesity
explained by genetic influences. Five genes affecting appetite have been discovered in mice,
including the gene leptin, which codes for a protein that is expressed by adipose tissue. When an
individual has a deficiency or resistance in leptin, it is thought that the individual overfeeds,
eventually leading to obesity. However, current literature suggests obesity develops
multifactorially, from a combination of genes, the environment, and behavior2.
Most successful weight loss comes from a combination of low caloric diets, behavior
modification, exercise, and social support. Due to high relapse rates, much emphasis must be
placed on the maintenance of weight loss over time. Several medications have been approved by
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the FDA, including short-term anticholaminergic medications such as phentermine,
diethylpropion, and mazindol. Two long-term medications include sibutramine, which blocks the
uptake of serotonin and norepinephrine in the central nervous system, and orlistat, which reduces
fat absorption. Over the counter medications include bitter orange extract, chitosan, chromium,
conjugated linoleic acid (CLA), among many others. Bariatric surgery may also be indicated in
the morbidly obese, and can result in over 50% of body weight loss after one year2.
While the above prescription medications are effective, only 20% of patients using these
prescription medications will lose 20 lb and maintain the loss for only 2 years, even with diet and
exercise. Average weight loss using diet and exercise alone is about 7% of initial baseline
weight, and many of these patients even after the 7% loss will still continue to have a BMI in the
obese category2. Currently, there are no long-term studies to support that prescription medication
can maintain long-term weight loss. Sibutramine, which is no longer available, contained many
side effects, including dry mouth, anorexia, constipation, insomnia, and dizziness. Orlistat has
been linked to the proliferation of aberrant crypt foci, which are precursors to colon cancer. Up
to 40% of patients who receive bariatric surgery experience side-effects, including post-operative
wound infections, gastric bleeding, and death3. However, an over-the-counter supplement,
conjugated linoleic acid, may provide satisfactory weight loss that causes less adverse effects
than prescription medications or surgery. CLA is the first ingredient listed in many popular overthe-counter weight loss supplements, and is also sold in a pill form.
OBJECTIVE
The objective of this systematic review is to determine ―the safety and efficacy of conjugated
linoleic acid used for weight loss in obese individuals‖.
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METHODS
The criteria for selection of the studies included obese patients who are otherwise healthy
between the ages of 18-65 years. Inclusion criteria for each of the studies utilized BMI, however,
each criteria was slightly different. Gaullier et al. accepted subjects with a BMI range of 28-32
kg/m2, Watras et al. accepted a BMI range of 25-30 kg/m2, and Whigham et al. accepted a BMI
of 27 – 35 kg/m2. Each study had exclusion criteria of any subjects on drug therapy were not able
to participate. The Gaullier et al. and Whigham et al. studies also excluded pregnant subjects and
patients with serious medical conditions.
The intervention used was the administration of CLA for weight loss. In each study,
results are compared between the groups receiving CLA 3.4g/day (Gaullier et al.)4, CLA 4g/day
(Watras et al.)5, or 6g/day (Whigham et al.)6against a placebo. According to the patients in all
three studies, CLA is a safe method for weight loss reduction. CLA was an effective weight loss
supplement in both the Gaullier et al. and Watras et al. studies, however, in the Whigham et al.
study, patients did not have any significant weight change. The types of studies included were
randomized control trials, double-blind, and placebo-controlled.
The three randomized control trials in this review were all double-blind clinical trials
with the intention to treat and with subjects being either overweight or obese based on clinical
criteria. The Gaullier et al. study had the greatest number of participants with 118, and a
withdrawal of 25. Whigham et al. started with 64 participants, and had 8 withdrawals. The
Watras et al. study had 48 patients and had 8 withdrawals. In the Gaullier study, participants
were given 3-4 g/CLA a day, while Whigham et al. administered 3.2g/CLA a day, and Watras et
al. administered each participant 6g/CLA a day.
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Key words in the literature searches were conjugated linoleic acid, CLA, body
composition, overweight, safety, efficacy, adverse effects, and obesity. All articles searched were
in peer-reviewed journals and all articles were published in English. Literature searches were
conducted using the OVID MEDLINE and Cochrane databases. Articles were selected based on
relevance and that the outcomes of the studies mattered to patients (POEMS). Articles that were
published before October 2002 were excluded due to a Meta-Analysis written at that time.
Studies included were conducted in a randomized, controlled fashion in a prospective, intentionto-treat basis, dated after Oct. 2002. Statistics used to report the data included p values, Fisher’s
exact test, a X2 test, a t-test, and numbers needed to treat (NNT). Demographics of included
studies are provided in Table 1.
Table 1: Table of demographics of included studies
Study

Type

# Pts

Age
(yrs)

Inclusion
Criteria

Exclusion Criteria

W/D Interventions

Gaullier,
2007

Double
blind,
RCT

118

18-65

BMI 2832 kg/m2

Drug therapy, special diet or
taking dietary substitutes for
weight loss 2 weeks prior to the
study, CLA consumption before
the study, pregnant and lactating
women, DM type II, HTN, renal
disease, cardiac failure, malignant
tumors, alcohol use, thyroid
disease, drug abuse.

25

3-4 g/d of conjugated
linoleic acid vs a
placebo for 6 months

Double
blind,
RCT

48

18-44

BMI 2530 kg/m2

Drug therapy

8

3.2 g/d of conjugated
linoleic acid vs a
placebo for 6 months

Double
blind,
RCT

64

18-50

BMI 27 –
35 kg/m2

Unstable weight, no serious
medical conditions, no interfering
dugs, and not pregnant or
lactating.

17

6g/day of conjugated
linoleic acid vs a
placebo for 5 months

(1)

Watras,
2003
(2)
Whigham,
2004
(3)
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OUTCOMES MEASURED
The outcomes measured in all three studies included both the change in body weight prior
to and after treatment with CLA, and also the side effects in comparison to the treatment.
Gaullier et al. measured body weight, BMI, vital signs, and complete blood work every three
months. Whigham et al. had subjects follow up every two weeks for complete blood work and
body composition by water dilution. Also every month, a body composition by BodPod® was
performed monthly until the end of the study. Food intake and exercise diaries were submitted at
each clinic visit. Watras et al. measured body weight monthly using Selinger’s four-component
model to calculate body fat mass: %BF = ((2.747/BD/Wt) – (0.7141(TBW/Wt)) + (1.146 *
(TBM/Wt) – 2.0503) x 100, where %BF is percent body fat, BD is body density (kg/ l), Wt is
body mass (kg), TBW is total body water (kg), and TBM is total body mineral (kg) calculated
from a DXA scan. At months 0 and 6, blood chemistry work was performed on each subject.
Gaullier et al. defined an adverse effect as any unfavorable, unintended event. Adverse
effects were divided into serious or non-serious. A serious adverse effect was defined as a lifethreatening effect. Non-serious adverse effects were recorded every 3 months, while adverse
effects were monitored continuously throughout the study. Whigham et al. used an adverse
events questionnaire every two weeks to determine adverse effects. To measure adverse affects,
Watras et al. used a 36 question questionnaire monthly throughout the study. Symptoms were
grouped into four categories: cold or flu, general symptoms like nausea and headache, orthopedic
symptoms such as joint and back pain, and emotional symptoms such as depression and
irritability.
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RESULTS
Table 2 compares placebo vs. CLA (3.4g/d) over a six month time period in the Gaullier
et al. 2006 study. The comparative effects were made using a paired t test, comparing from
baseline and at 6 months time. Categorical variables were analyzed using Fisher’s exact test or a
X2 test. DEXA was used to determine the change of body fat mass (BFM) and comparisons
between baseline and 6 months were performed using analysis of covariance. Compared to the
placebo, CLA significantly decreased body fat mass (p=0.043), arm fat mass (p=0.027), leg fat
mass (p= <0.001), and abdominal fat mass (p=0.027). However, the comparison between placebo
and CLA for lean body mass (p=0.22) and bone mineral content (p=0.36) did not meet statistical
significance. When comparing baseline to the six months period, it was found that BMI for all
the subjects had a significant change (p=0.031) and when comparing the six month time period
to only subjects who started with a BMI over 30kg/m2, it was found that the reduction of weight
by CLA was even more significant (p=0.020)
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Table 2. Summary of Placebo vs. 3.4 g/day Conjugated Linoleic Acid (CLA) Comparing Body
Fat Mass, Lean Body Mass (BFM), Bone Mineral Content (BMC), Arm Fat Mass (AFM), Leg
Fat Mass (LFM), Abdominal Fat Mass (TFM), and Body Mass Index (BMI) Over a Period of 6
Months
Gaullier et al. 2006
Placebo

CLA 3.4g/day

p-value

BFM

-1.0 (kg)

+0.2 (kg)

0.043

LBM

-0.5 (kg)

+0.3 (kg)

0.22

BMC

0.0 (kg)

0.0 (kg)

0.36

AFM

-0.4 (kg)

-0.3 (kg)

0.027

LFM

-0.5 (kg)

+3.0 (kg)

<0.001

TFM

+0.3 (kg)

-0.2 (kg)

0.068

BMI

+0.1 (kg/m2)

-0.5 (kg/m2)

0.031

BMI > 30kg/m2 1

+0.1 (kg/m2)

-5.0 (kg/m2)

0.020

1

Subjects initially started with a BMI over 30kg/m2

Table 3 shows the results from the Watras et al. study. The primary outcome variable of
was the change in body fat mass and that was measured using the four-component model. The ttest was used to determine differences between the groups at month 0 for all the variables. The
results show that the 6 month loss in body fat was significantly greater with CLA compared to
the placebo (p=0.02). The results also show a significant reduction in BMI with CLA compared
to the placebo (p=0.05). There was no difference in the in the change in the fat-free mass (p=0.8)
or abdominal fat mass (p=0.1).
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Table 3. Summary of Placebo vs. 3.2g/day Conjugated Linoleic Acid (CLA) Comparing Body
Weight, Body Mass Index (BMI), Fat-free mass (FFM), and Abdominal Fat Mass (Abd. FM)
Over a Period of 6 Months
Watras 2006
Placebo

CLA 3.2g/day

Month 0

∆ (6-0 mo.)

Month 0

∆ (6-0 mo.)

p-value

Body weight (kg)

79.0 + 10.9 *

1.1 + 3.2

80.0 + 9.1

-0.6 + 2.5

0.02

BMI (kg/m2) 1

28.0 + 2.2

0.4 + 1.1

27.6 + 1.8

-0.2 + 0.9

0.05

FFM (kg) 2

28.4 + 5.0

0.7 + 3.0

26.6 + 5.5

-1.0 + 2.2

0.8

Abd. FM (kg) 3

7.5 + 1.5

0.2 + 1.2

6.9 + 1.5

-0.2 + 1.0

0.1

*

All values are x + standard deviation
The Whigham et al. 2004 study used ANOVA models to analyze dated for body

composition analysis. However, instead of displaying data, Whigham et al. stated that there were
no significant changes overall in body weight or body fat between the CLA group and placebo
after 12 months. The Whigham et al. study primarily focused on adverse effects of CLA.
Adverse events were noted throughout all three trials. Whigham et al. noted significantly
lower frequencies of skin rash, depression, irritability/anger, hair loss, and infection in the CLA
group vs. placebo. Watras et al. noted that the rate of cold and flu symptoms increased with CLA
(p = 0.02) and placebo (p <0.0001). There was a decrease in emotional symptoms such as
anxiety and depression in the CLA group that was significantly different from the placebo group
(p = 0.04). Gaullier 2006 et al. noted that there were similar adverse events in both groups
(p=0.85). Most of the adverse events were related to the gastrointestinal or musculoskeletal
systems. The numbers needed to harm (NNH) for the Gaullier et al. study was 20. Blood
chemistries for safety profiles were also recorded in each study. In all three studies, levels of
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change of glucose, insulin, ALT, and AST did not meet statistical significance between the
placebo and CLA at the end of each study period as shown in Table 4.
Table 4. Summary of Change in Glucose, Insulin, ALT, and AST Levels in Studies
Gaullier et al. 2006
Watras et al.2006
Whigham et al.2004
∆ (6-0
mo.)

∆ (6-0
mo.)

∆ (6-0
mo.)

∆ (6-0
mo.)

CLA
3.4/day

Placebo

CLA
3.2
g/day

Placebo

Glucose
(mg/dl)

-0.48 +
0.81*

-0.4 +
0.74

0.40

2.8 +
4.9

6.1 +
5.9

Insulin
(µU/ml)

-3.2 +
33.6

8.7 +
72.3

0.93

2.1 +
11.6

ALT
(U/I)

-0.20 +
13.64

†

0.92

AST
(U/I)

-1.14 +
7.91

†

0.14

p-value

∆ (52
wks)

∆ (52
wks)

CLA
6g/day

Placebo

NS1

†

†

-0.6 +
6.2

NS

1.78 +
0.19

1.83 + - NS
0.20

-2.5 +
20.7

6.6 +
17.3

NS

†

†

NS

-4.2 +
4.8

-3.0 +
7.4

NS

†

†

NS

p-value

p-value

NS

*

All values are x + standard deviation
† Data not reported
1
NS = Not significant, P >0.05
DISCUSSION
Conjugated linoleic acid has been a foremost ingredient on many dietary supplement
pills. The articles reviewed studied CLA and its effect on adults over the age of 18, However,
recent studies have shown that CLA may be a proven beneficial weight loss supplement for
children. Racine et al. 2010 studied children ages 6-10, and found that after 7 months of 3g/d of
CLA vs. placebo, subjects had a decrease in body fatness7.
Although most studies have reported that CLA does not cause harmful, adverse effects, a
study by Risérus et al. 2007 found that CLA may cause an increase in oxidative stress, which can
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lead to insulin resistance. In a double-blind placebo-controlled trial, 60 men with metabolic
syndrome received either CLA or a placebo for 12 weeks. It was found that CLA caused an
increase in inflammatory markers and oxidative stress in men in the 12 week time. However,
more studies are needed over a longer time period to truly establish CLA’s effects on insulin
resistance8.
Limitations to all three studies were the lack of duration and number of test subjects used.
Both the Gaullier et al. and Watras et al. studies only performed a six month study, while
Whigham et al. study lasted a year. Longer studies are needed to determine long-term efficiency
and adverse effects. Another limitation is that dietary supplements in the market are variable in
quality and in the amounts of CLA they contain. The results of these studies may not be
appropriate to generalize for all CLA products, due to the quality of the isomers used and the
variable amounts of CLA the studies used, vs. the amounts found in weight loss supplements.
The Watras et al. study had its own limitation, in that the subjects consisted of 80% overweight
women. Because of this ratio, it may not be appropriate to generalize the data to men as well,
considering the high percentage of women used in the study.
CONCLUSION
Based on blood work and reported adverse effects, the studies reviewed demonstrate that
conjugated linoleic acid was found to be safe for human consumption. However, the Gaullier et
al. and Watras et al. studies found that CLA did cause weight loss in subjects, while the
Whigham study found no correlation between weight loss and CLA intake. Future studies should
be designed to determine the correlation between CLA and weight loss. The studies in this
review used age ranges from 18-64. However, more specific age studies should be conducted,
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such as using ages 18-30, 30-40, etc. Also the studies did not use a set number of subjects per
age range, instead many of the subjects were in their 50’s and 60’s. This alone can affect the
results of weight loss, as it is harder to lose weight as an individual’s age increases. In the future,
studies should be designed either using an equal number of men and women, or a specific study
should be conducted for men or women alone. Each study used different grams of CLA per day,
however, a study should divide subjects and use different amounts, such as one group with
3g/day, another with 6 g/day, and a another on 9 g/day to truly see a difference in weight loss or
adverse effects. Finally, the studies should be conducted over a longer period of time. Whigham
had the longest study for a year, but two year studies should be conducted to truly determine
long-term effects on weight loss and adverse reactions to CLA. Performing research with the
adjustments in research studies will provide a more accurate answer to CLA’s efficiency and
safety.
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